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A B S T R A C T
Estrogen withdrawal, a characteristic of female aging, is associated with age-related intervertebral disc
(IVD) degeneration. The function of estrogen is mediated by two classic nuclear receptors, estrogen
receptor (ER)-a and -b, and a membrane bound G-protein-coupled receptor 30 (GPR30). To date, the
expression and function of GPR30 in human spine is poorly understood. This study aimed to evaluate
GPR30 expression in IVD, and its role in estrogen-related regulation of proliferation and apoptosis of disc
nucleus pulposus (NP) cells. GPR30 expression was examined in 30 human adult NP and 9 fetal IVD.
Results showed that GPR30 was expressed in NP cells at both mRNA and protein levels. In human fetal
IVD, GPR30 protein was expressed in the NP at 12–14 weeks gestation, but was undetectable at 8–
11 weeks. The effect of 17b-estradiol (E2) on GPR30-mediated proliferation and interleukin-1b (IL-1b)-
induced apoptosis of NP cells was investigated. Cultured NP cells were treated with or without E2,
GPR30 antagonist G36, and ER antagonist ICI 182,780. NP cell viability was tested by MTS assay. Apoptosis
was determined by ﬂow cytometry using ﬂuorescence labeled annexin-V, TUNEL assay and
immumnocytochemical staining of activated caspase-3. E2 enhanced cell proliferation and prevented
IL-1b-induced cell death, but the effect was partially blocked by G36 and completely abrogated by a
combination of ICI 182,780 and G36. This study demonstrates that GPR30 is expressed in human IVD to
transmit signals triggering E2-induced NP cell proliferation and protecting against IL-1b-induced
apoptosis. The effects of E2 on NP cells require both GPR30 and classic estrogen receptors.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Intervertebral disc (IVD) degeneration is one of the leading
causes of chronic back pain, with both a high prevalence and
associated disability in a recent global burden of disease study [1].
Characterized by a loss of cells and extracellular matrix leading to
disc height reduction [2,3], IVD degeneration is driven at least in
part by aging [4]. Collagens and proteoglycans appear to undergo
speciﬁc age-related changes which inﬂuence matrix quality and
integrity or alter cellular reparative pathways, potentially contrib-
uting to degeneration [4,5].* Corresponding author at: Orthopedic Research Institute and Department of
Orthopedic Surgery, St George Hospital, Level 2, 4-10 South Street, Kogarah NSW
2217, Australia. Fax: +61 2 8566 7177.
E-mail addresses: a.diwan@spine-service.org, a.diwan@unsw.edu.au
(A.D. Diwan).
http://dx.doi.org/10.1016/j.jsbmb.2016.01.012
0960-0760/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article unPathological apoptosis has been shown to be a key factor
responsible for the decrease in cell number in nucleus pulposus
(NP) during disc degeneration [6]. Consequently, prevention of NP
cell apoptosis could slow down the progression of IVD degenera-
tion. 17b-estradiol (E2) has been shown to promote human
annulus ﬁbrosus (AF) cell proliferation [7], and to exert anti-
apoptotic effects in rat disc cells [8,9]. However, the anti-apoptotic
effect of E2 in human NP cells remains unknown.
Estrogen exerts a range of biological effects in a variety of
tissues, including the musculoskeletal system and connective
tissues [10,11]. Estrogen also plays an important role in the
regulation and maintenance of healthy spinal discs in women [12].
Withdrawal of estrogen at menopause has a negative effect on the
structure of bone and IVD. In particular, elderly females experience
a faster rate of lumbar disc degeneration with greater severity than
age matched men, despite the frequency of lumbar disc
degeneration being higher in young and middle-aged men than
in women [13,14]. Further, degenerative lumbar spondylolisthesis,
most common at the L4/L5 level, was nearly threefold higher inder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mized controls [15]. Indeed, ovariectomy caused lumbar IVD
degeneration in a rodent model [16]. Estrogen replacement
therapy (ERT) has beneﬁcial effects in maintaining disc height,
an indicator of disc degeneration, where estrogen-repleted women
maintained higher disc heights than untreated post-menopausal
women [17,18].
G protein-coupled receptor 30 (GPR30), a 7 transmembrane
spanning G protein-coupled receptor with high afﬁnity for
estrogen [19], was localized at the cell membrane, in subcellular
compartments and within the nucleus of normal or cancer cells,
involving in estrogen evoked physiological and pathological events
in central nervous, immune, renal, reproductive and cardiovascular
systems [20,21]. GPR30-mediated estrogenic signaling was shown
to activate multiple intracellular signaling pathways including
mobilization of intracellular calcium and activation of protein–
lipid kinase pathways [22,23]. Its presence has been touted to
facilitate rapid non-genomic signaling events to result in cell
migration, survival and proliferation that are independent of
classic estrogen receptor a or b (ERa or ERb) in a variety of normal
and malignant cell types [11,22,24]. More recently, genomic
signaling mechanism of GPR30 has been identiﬁed as the receptor
nuclear translocation in an importin-dependent manner [21].
The responsiveness to estrogen of a given tissue is determined
by the expression of ER and GPR30, their co-regulator expression
and the signaling interplay between receptors [25]. Expression of
both ERa and ERb has been detected in human disc NP and AF,
with signiﬁcantly decreased expression concomitant with the
aggravation of IVD degeneration [7,26]. However,
GPR30 expression and its physiological role in relation to estrogen
function in IVD remains unclear. In this study, we aimed to
investigate whether GPR30 was expressed in the NP tissue of
human IVD at various stages of life, and if so whether it plays a role
in transmitting E2 signals for cell proliferation and survival, both
aspects relevant to disc regeneration and health.
2. Materials and methods
2.1. Tissue collection
The human NP tissues were freshly collected from elective
surgeries following informed consent under ethical approval from
the South-Eastern Health Service Human Research Committee,
Sydney, Australia. A total of 37 disc samples were collected from
30 patients, in total of 9 female and 21 male samples with a median
age of 41 15 and 39  14 respectively. Nine of the 37 disc samples
were obtained from 6 scoliotic patients (age 13–31, 23  7, 2 female
and 3 male). The other 28 disc samples were obtained from
24 patients (age 27–79, 46  13, 7 female and 17 male) with
moderate signs of degeneration, including decreased water
content and disc height, as determined by magnetic resonance
imaging (MRI) and X-ray. Seven of the 37 samples were used forTable 1
Percentage of GPR30 mRNA and protein expression detected in NP samples.
GPR30 positive samples (%)
RT-PCR (n = 12) IHC (n = 30)
Adult tissue
Female 80% (4/5) 78% (7/9)
Male 71% (5/7) 67% (14/21)
Total 75% (9/12) 79% (21/30)
Foetal tissue
8–11 Weeks n/a 0% (0/4)
12–14 Weeks n/a 80% (4/5)
IHC = Immunohistochemistry.cell culture experiments, and 30 of the samples were used for both
histology and RNA analysis.
The spinal columns of 9 human fetuses at 8–14 weeks gestation
were obtained at termination of pregnancy with ethical approval
from the Human Care and Ethics Review Committee of the
University of New South Wales. No genetic abnormalities were
reported for these specimens. The sex of each sample was not
provided. Tissue was freshly collected and immediately ﬁxed in
10% neutral buffered formalin for 24 h followed by sectioning in the
sagittal plane and embedding in parafﬁn. Details of tissue analyses
in this study are provided in Table 1.
2.2. RNA extraction and RT-PCR
Freshly collected NP tissues were ground to powder in liquid
nitrogen using a mortar and pestle. Total RNA from tissues was
isolated using TRIzol reagent (Life Technologies, Carlsbad, CA) and
from cultured cells using H-RNA puriﬁcation kits (Roche Diag-
nostics, Manheim, Germany) according to manufacturers’ instruc-
tions. The cDNA was generated by reverse transcription of 1 mg of
total RNA using SuperScript III ﬁrst-strand synthesis kit (Life
Technologies). The 1:40 diluted cDNA was used in 20 ml reactions
for PCR analysis using a Rotor-Gene RG3000 system (Corbett Life
Science, Sydney). The thermal proﬁle for all reactions was as
follows: 5 min at 95 C, followed by 40 ampliﬁcation cycles of 15 s
at 95 C, 30 s at 60 C and 30 s at 72 C [22]. The primers were
designed based on published mRNA sequences using the
Primer3 online tool. GPR30 (GenBank accession no.
NM_001505): forward primer: 5-CTCTTCCCCATCGGCTTTGT-
3 and reverse primer: 5-TACAGGTCGGGGATGGTCAT-3. Glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) (GenBank accession
no. NM_001034034.1): forward primer: 5-GAGTCCACTGGGGTCTT-
CACT-3; and reverse primer: 5-GCGTGGACAGTGGTCATAAGTC-3.
The PCR end products of GPR30 and GAPDH were analyzed by
electrophoresis in 10% polyacrylamide gels and the DNA bands
were visualized with ethidium bromide.
2.3. Immunohistochemical and immunoﬂuorescence staining
Parafﬁn embedded blocks of tissue were cut into sections
(4 mm) and mounted on superfrost plus slides (Thermo Fisher,
Australia). The slides were deparafﬁnized and hydrated through a
graded ethanol series. After antigen retrieval, endogenous
peroxidases were scavenged with 3% (v/v) H2O2 and non-speciﬁc
binding was blocked by incubation in 10% skim milk in Tris-HCl
buffer. The slides were then probed with a primary rabbit anti-
GPR30 polyclonal antibody (1:150, Santcruz, Australia). Thereafter,
the slides were washed and treated with multilink solution (DAKO,
Sydney, Australia) followed by streptavidin-conjugated peroxidase
incubation. The sections were visualized with a 3, 30-diamino-
benzidine hydrochloride solution (DAB, DAKO) and counterstained
in haematoxylin. The primary antibody was omitted for a negative
control. The images were captured using a Leica DMLB microscope.
Immunoﬂuorescence staining was performed on cells cultured
on glass coverslips following ﬁxation with 4% paraformaldehyde.
Cells were stained with or without a permeabilization step with
0.1% Triton X-100, blocked in 5% normal goat serum. Primary
polyclonal rabbit antibody against GPR30 (Santcruz) was diluted
1:200 before applying to slides, followed by incubating with Alexa-
488 conjugated anti-rabbit IgG secondary antibody in 1:500 dilu-
tion. The slides were counterstained with a 500 nM of propidium
iodide (PI, Sigma). Finally, mounted coverslips were visualized
under a laser scanning confocal ﬂuorescence microscope (Olympus
Sverige AB, Solna, Sweden).
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Freshly obtained NP tissues were immediately subjected to
0.025% collagenase digestion overnight. Subsequent primary cell
cultures were grown in a complete medium containing DMEM
(Life Technologies),10% fetal bovine serum (FBS), and 1% penicillin/
streptomycin at 37 C, 5% CO2/95% air until reaching conﬂuence. All
experiments were conducted using cell cultures at passage 1–2.
For experiments, cells were seeded in DMEM medium with 1%
FBS overnight. Cells were then pre-treated with GPR30 antagonist
G36 (250 nM), and/or the estrogen receptor (ERa and ERb)
antagonist ICI 182,780 (200 nM) for 1 h prior to treatment with E2
(50–100 nM) for 48 h. The cells in the control groups were
incubated for equivalent periods of time without further treat-
ment. For immunocytochemistry and immunoﬂuorescence stain-
ing, cells were sub-cultured at a concentration of 5 104/ml in
6 well plates with glass cover slips for 2 days before assay.
2.5. Cell proliferation
Cell survival was measured with the MTS cell proliferation
assay kit (Promega, Madison, WI) using 1 104 cells/well in 96-
well plates. To observe the effect of estrogen on NP cell
proliferation, different concentrations of E2 (50–100 ng/ml) were
applied to the cultures. Assays were performed as speciﬁed by the
manufacturer, such that only viable cells are able to metabolically
reduce tetrazolium salts to formazan salts, detected directly in a
spectrophotometer at 490 nm.
2.6. Apoptosis detection
2.6.1. TUNEL assay
The effect of E2 on NP cell apoptosis was further examined
using DeadEndTM ﬂuorometric TUNEL kit (Promega Corporation,
Madison, USA,) as per the manufacturer's instruction. Brieﬂy, NP
cells were cultured on coverslips and then apoptosis was induced
using interleukin-1b (IL-1b) (R&D Systems, Minneapolis, MN) at
20 ng/ml in serum-free culture condition for 48 h. The cells were
ﬁxed in 4% paraformaldehyde and treated with permeabilization
solution consisting of 0.1% Triton X-100 for 20 min. After washing,
the cells were incubated with labeling solution containing
terminal deoxynucleotidyl transferase and ﬂuorescein dUTP for
2 h. Cells were then washed and double stained with 1 mg/ml DAPI
for 10 min. The labeled NP cells were examined under a
ﬂuorescence microscope (Olympus, Germany). To quantify apo-
ptotic cells, the TUNEL positive cells in 3 independent culturesFig. 1. Expression of GPR30 mRNA in the nucleus pulposus of human intervertebral dis
shows the PCR products of GPR30 (top panel) and GAPDH (bottom panel) separated on a D
in the representative image (n = 3).were counted in 5 replicates of 5 randomly selected ﬁelds. The
green ﬂorescent stains are TUNEL positive cells and blue nuclei
staining represents the total number of cells. The proportion of
TUNEL positive cells was expressed as a percentage of the total
cells.
2.6.2. Flow cytometry
The population of induced apoptotic cells was determined
using the Alexa Fluor-488 conjugated annexin-V cell death
detection kit (Life Technologies) as speciﬁed by the manufacturer.
Brieﬂy, IL-1b apoptotic induction was performed with 20 ng/ml for
48 h. E2 at a concentration of 50 nM was added in cultures and
remained in the medium during IL-1b treatment. Either G36 or ICI
182,780 or a combination of both was pre-administrated in
cultures for 0.5 h in corresponding co-treatment groups. After
incubation for 48 h, cells were harvested and incubated with the
Alexa Fluor-488 annexin-V in binding buffer at room temperature
for 15 min in the dark. The cells were measured by a ﬂow
cytometer—FACSCanto II and the data were analyzed with
FACSDiva software (BD Biosciences, CA, USA).
2.6.3. Activated caspase-3 by immunocytochemistry
Activated caspase-3 was detected by immunocytochemical
staining. Brieﬂy, NP cells were subcultured on glass coverslips and
ﬁxed with 4% paraformaldehyde, followed by blocking of
nonspeciﬁc binding with a 10% skim milk solution. Primary mouse
anti-cleaved caspase-3 antibody (1:100, Cell Signaling Technology)
was added to each coverslip, incubated at 4 C for 12 h. After several
washes with PBS, cells were incubated using multilink solution and
visualized with 3,30-diaminobenzidine hydrochloride solution
(DAKO).
2.7. Statistical analysis
Data analysis of multiple experimental groups was performed
with one way analysis of variance (ANOVA) followed by Duncan’s
test using SigmaStat software (SPSS, Inc., San Rafael, CA). Differ-
ences were considered signiﬁcant at p < 0.05.
3. Results
3.1. GPR30 is expressed in human NP tissue and cultured NP cells
GPR30 mRNA expression was detected in 4 out of 5 male and
5 out of 7 female adult NP tissue samples (Fig. 1, Table 1).
Immunohistochemical staining identiﬁed positive GPR30 proteinc. RT-PCR detection of GPR30 mRNA levels in 12 human NP samples. The gel image
NA-retardation gel of 10% polyacrylamide. Lanes 1–12 represent the 12 NP samples
Fig. 2. (A) representative images of GPR30 immunohistochemical localisation in human nucleus pulposus tissues. Images show NP tissue stained with GPR30 speciﬁc
antibody at low magniﬁcation (a and b) and the boxed regions at higher magniﬁcation (c and d). Strong expression of GPR30 associated with the cell nucleus region is visible in
tissue samples derived from both scoliotic (a and c), and degenerative discs with proliferative cell clusters (b and d). Weaker staining is shown towards the cell periphery at the
NP cell plasma membrane (d arrow). No GPR30 expression was observed in the negative controls where the ﬁrst antibody was omitted (e). Original magniﬁcation: a, b and e
20; c and d 100. (B) GPR30 immunohistochemical localization in human fetal NP tissue. Images show speciﬁc GPR30 antibody staining of fetal spinal tissue sections at 8
weeks (a and c) and 13 weeks (b and d) gestation. Tissues are shown at low magniﬁcation (a and b, 10) with boxed regions at higher magniﬁcation (c 100, d 40).
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9 were from female tissues and 14 out of 21 were male (Table 1).
There was no signiﬁcant difference in the GPR30 expression
pattern in tissues derived from either degenerated or scoliotic
tissues (Fig. 2A). Strong GPR30 protein expression was predomi-
nantly localized in the nucleus in all of the samples (Fig. 2A a–d),
but was also detected in the plasma membrane of some NP cells
(Fig. 2A a–d, arrow). No antibody staining was detected in the NP
cells of the negative control (Fig. 2A e).
In human fetal tissue, GPR30 protein was detected in the
developing nucleus pulposus of the disc. Strong brown staining
was visible in NP cells in specimens from 12 to 14 weeks gestation
(Fig. 2B b and d) but not at earlier time points between 8 and
11 weeks gestation (Fig. 2B a and c). Positive staining was visible in
the cytoplasm of notochordal cells in the NP region, but most
nuclei appeared to be stained blue with haematoxylin, lacking
GPR30 antibody binding (Fig. 2B d). Staining did appear to bepresent at the plasma membrane in cells of the NP, with
intracellular staining concentrated in regions near the nucleus
(Fig. 2B b and d).
To further investigate the localization of GPR30 in NP cells,
immunoﬂuorescent staining was performed and analyzed by
confocal microscopy. Consistent with the aforementioned obser-
vations in immunohistochemical staining, immunoﬂuorescent
staining conﬁrmed that GPR30 protein expression was present
in all cultured NP cells (Fig. 3). GPR30 expression on Triton X-100-
permeabilized cells was found to have more extensive distribution
across the cell, and was concentrated in the region of the nucleus
(Fig. 3 a–f), including extrusions of the cellular membrane (Fig. 3 d
and f). By comparison, intact cells showed a more restricted,
punctate staining pattern that failed to outline the cell (Fig. 3 g–i).
No GPR30 expression was detected in the negative controls lacking
primary antibody (not shown).
Fig. 3. Confocal microscopic images of GPR30 immunoﬂuorescence in cultured human nucleus pulposus cells. Representative images show expression of GPR30 (green) on
cultured NP cells either Triton X-100-permeabilized (A–F) or intact (G–I). Nuclei are stained using propidium iodide (PI, red). Co-localization of GPR30 with PI is observed
when images merge (yellow; C, F, I) (original magniﬁcation: 600). Images represent three independent tissue samples cultured in duplicate, with individual experiments
performed in triplicate. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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proliferation
The data from MTS assay showed that E2 could stimulate NP cell
proliferation. To observe if GPR30 signaling is required in the
E2 induced cell proliferation, NP cell cultures were stimulated with
increasing concentrations of E2 (0–100 nM) with or without
speciﬁc estrogen receptor antagonists G36 (for GPR30) or ICI
182,780 (for ERa/ERb). Initial titration experiments showed peak
stimulation at 50 nM E2, reaching a plateau at 100 nM with an
approximately 1.5 fold increase when compared to control (data
not shown). Further experiments were performed using 50 nM of
E2 stimulation. NP cell proliferation was found to increase by up to
52% after 48 h exposure to E2 when compared with control
(p < 0.05) (Fig. 4). Addition of either G36 or ICI 182,780 to NP cell
cultures alone had marginal, but not signiﬁcant effect on cell
proliferation. Co-treatment with either G36 or ICI 182,780 and
E2 resulted in partial blockage of E2-stimulated proliferation.
Furthermore, treatment with a combination of G36 and ICI 182,780
completely inhibited E2stimulated NP cell proliferation (p < 0.05)
(Fig. 4), indicating the involvement of both ERs and GPR30 in
E2 mediated signal transduction.
3.3. GPR30 blockage partially reverses estrogen inhibited NP cell
apoptosis
To investigate the potential role of E2 in protecting cells from IL-
1b-induced apoptosis and the involvement of GPR30, we ﬁrst
utilized the TUNEL assay, analyzing DNA fragmentation. IL-1b
treatment of NP cells for 48 h signiﬁcantly increased thepopulation of cells with positive TUNEL staining by 39% compared
to control (p < 0.01, Fig. 5A, B). E2 appeared to exert a protective
effect on IL-1b induced NP cell damage (p < 0.05), with fewer cells
showing positive TUNEL staining (Fig. 5A). Co-treatment with
either G36 or ICI 182,780 alone did not signiﬁcantly block the
protective effect of E2. However, the E2 effect was completely
abolished by co-treatment with both G36 and ICI 182,780 (Fig. 5A
and B).
The involvement of GPR30 in E2 signaling was further assessed
using annexin-V staining and then analyzed by ﬂow cytometry. IL-
1b treatment for 48 h increased the number of apoptotic NP cells
staining positive for annexin-V in culture to 29%, compared to 3% in
the control (Fig. 6). E2 decreased the percentage of apoptotic cells
to 8%, an approximately 2.5 fold decrease compared to IL-1b
treatment alone (29%) (Fig. 6), indicating that E2 is able to reduce
IL-1b-induced apoptosis in NP cells. Treatment in the presence of
GPR30 antagonist G36 produced a partial reduction of E2 effect,
with 12% apoptotic cells detected. The protective effect of E2 was
completely abolished by the addition of both estrogen receptor
antagonists ICI 182,780 and G36 (Fig. 6).
3.4. GPR30 blockage partially offsets estrogen reduced casepase-
3 activation
Using immunocytochemistry, we investigated the activation
status of caspase-3, a marker of apoptosis, in resting and
E2 stimulated NP cells. Immunostaining showed that cells cultured
with medium alone for 48 h did not possess activated caspase-
3 protein expression (Fig. 7). Activated caspase-3 levels were
signiﬁcantly increased in NP cells after stimulation with 20 ng IL-
E2 _ + + +
G36 _ _ + _ +

























Fig. 4. E2 promoted cellular proliferation requires both ERs and GPR30. E2 treated
intervertebral disc (IVD) cells showed signiﬁcantly enhanced cellular proliferation
when compared with control or co-treatment with G36 + ICI 182,780. Graph shows
cell proliferation with the addition of E2 alone, E2 + G36, E2 + ICI 182,780,
E2 + G36 + ICI 182,780, G36 or ICI 182,780 alone. * indicates p  0.05 of comparison
between E2 alone and control or between E2 alone and E2 + G36 + ICI 182,780. Data
are presented as mean  SE of triplicates in ﬁve independent samples.
Fig. 5. Preventative effects of E2 on IL-1b induced disc cell apoptosis detected by
TUNEL assay. (A) Florescent microscope images of cultured disc NP cells stained
with either DAPI (blue) or TUNEL labeling (green) following treatment with either
media alone (control), IL-1b, IL-1b + E2, IL-1b + E2 + G36, IL-1b + E2 + G36 + ICI
182,780. Positive TUNEL staining indicative of apoptosis was present in IL-1b-
stimulated cell populations. Image magniﬁcation: 100. (B) Quantitation of
apoptotic disc cells (percentage of TUNEL positive cells) in the different treatment
groups. Data are presented as mean + SE from three independent experiments
(n = 3) (**p < 0.01). (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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resulted in signiﬁcantly reduced active caspase-3 protein staining.
Pre-treatment with GPR30 receptor antagonist G36 partially
restored caspase-3 staining in IL-1b-stimulated cells, and the
presence of both E2 receptor antagonists G36 and ICI 182,780 al-
most completely blocked the E2 effect, showing levels of caspase-
3 similar to that of IL-1b treatment alone (Fig. 7).
4. Discussion
GPR30 mediates estrogenic signals in various tissues, but its
expression and localization in human intervertebral disc was not
explored. In this study, expression of GPR30 in human fetal spine
and adult IVD tissue was demonstrated for the ﬁrst time. In the
adult IVD samples, expression of GPR30 was observed in NP tissue
and cultured NP cells at both mRNA and protein levels. GPR30 was
expressed in degenerated disc tissue at similar levels to that of the
scoliotic disc group. This suggests that, unlike the classical nuclear
estrogen receptors ERa and ERb [26], even degenerated disc NP
cells may retain their potential to respond to estrogen through its
receptor GPR30 for tissue regeneration.
Pervious work has demonstrated that the highest levels of
GPR30 expression were observed in hypertrophic chondrocytes in
the human growth plate and that the level of GPR30 expression
declines as puberty progresses in both genders, suggesting that
GPR30 may be involved in chondrogenesis [27]. Other studies
performed on human bone tissue have shown that there is no sex
or age difference in GPR30 protein expression during puberty [28].
Our study of disc NP tissues also detected no sex or age differences
in GPR30 expression based on a small sample size. Since a
relatively low number of female samples and a median age of
41 15 indicative of a lack of female tissues of menopausal age, we
cannot draw conclusions regarding GPR30 expression during
menopause progression.
Estrogens play multiple protective roles in the musculoskeletal
system [10,11,29]. GPR30 clearly contributes to estrogen signaling
[25], with roles in glucose metabolism and skeletal bone growth
reported [30–32]. The contradictory roles of GPR30 in the
regulation of bone formation seem to result from gender speciﬁc
effects. In knockout mouse models, deletion of GPR30 reduced
bone growth in female mice [30,31], but increased bone growth in
male mice [32]. It has also been shown that GPR30 is required for
Fig. 6. Preventative effects of E2 on IL-1b-induced apoptosis in cultured disc NP cells detected by Alexa Fluor-488 conjugated annexin-V ﬂow cytometry assay. Figure shows
NP cells cultured in the presence of IL-1b, with the addition of combinations of E2, GPR30 antagonists G36 and/or ER antagonist ICI 182,780. The percentage of annexin-V
positive cells is shown represented in the upper boxed region.
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germ cell proliferation and fetal germ cell development [33]. We
detected what appeared to be temporal expression of GPR30 in the
developing human spine. Intracellular GPR30 expression was
detected in the fetal spine NP at 12–14 weeks gestation but was
absent or undetectable at 8–11 weeks. This may indicate a need for
the speciﬁc signal transduction in the NP by GPR30 at thatparticular stage of spinal development. Further studies are needed
to explore what speciﬁc purpose the expression of
GPR30 expression in disc cells may convey and how this impacts
on disc development.
In this study, we found that E2 could stimulate adult NP cells to
proliferate, demonstrating a protective effect of E2 in this disc
tissue. E2 induced cell proliferation was also shown in human
Fig. 7. Representative images of immunocytochemical staining of activated caspase-3 in disc NP cell cultures. Images show cultured NP cells treated with IL-1b and
combinations of E2 alone, of E2 and speciﬁc estrogen receptor antagonists G36 and/or ICI 182,780, stained with speciﬁc anti-caspase-3 antibodies. Control shows
unstimulated cells stained with anti-caspase-3 antibody. Image magniﬁcation: 400.
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plasmic expression of ERb. Similarly E2 stimulated disc cell
proliferation in animal models [9] and expression of ERa/ERb in
human NP cellshas been conﬁrmed [26]. Our current study
demonstrated GPR30 expression in human NP tissue and cultured
NP cells. When the NP cells were treated with either the
GPR30 antagonist G36 or the ERa/ERb antagonist ICI 182,780,
E2 stimulated proliferationwas partially suppressed, suggesting that
bothclassic ERand GPR30 contribute to E2signal transduction.There
may be other roles for this receptor in the disc that are yet to be
determined.
GPR30 has been previously localized to the plasma membrane
where it mediates rapid estrogen signal transduction [34,35], and
intracellular expression has also been reported in the endoplasmic
reticulum [22] and in the nucleus [21] of various types of cells. We
detected GPR30 protein expression in both plasma membrane and
intracellular compartments of NP cells, but the expression was
predominantly localized in the nucleus in all of the samples.
Receptors in the family of G protein-coupled receptors are linked tonon-genomic signal transduction mediated by complex intracel-
lular pathways, often involving rapid calcium mobilization and
cAMP elevation, a more rapid response to estrogen than the
traditional nuclear receptors ERa and ERb. While it remains
unclear whether its intracellular expression is of functional
signiﬁcance [22] or is a result of intracellular trafﬁcking, a recent
study demonstrated that a nuclear localization signal was within
the GPR30 protein sequence and an importin-dependent mecha-
nism facilitated receptor translocation into the nucleus in breast
cancer-associated ﬁbroblasts [21]. Importantly, nuclear localiza-
tion was functionally required, highlighting a potential alternative
mechanism of E2 action through GPR30. In this study, we did not
detect a rapid response to E2 stimulation in NP cells, rather the
E2 mediated changes were observed after 24 h stimulation with or
without ER inhibition. Although the E2 signal pathway through
GPR30 remains largely unknown in disc cells, it can be postulated
that GPR30 translocation into the nucleus was required for the cell
proliferation and protective effects of E2, which may be via an
importin-dependent mechanism.
54 A. Wei et al. / Journal of Steroid Biochemistry & Molecular Biology 158 (2016) 46–55IL-1b is an inﬂammatory cytokine that was previously shown to
induce apoptosis in intervertebral disc cells [36,37]. We have also
reported that IL-1b invokes apoptosis in human NP cell cultures, as
evidenced by elevated levels of annexin V, caspase-3 activity and
the induction of DNA fragmentation. In this study, the addition of
E2 was able to protect NP cell populations from IL-1b induced cell
death, consistent with reduced levels of caspase pathway
intermediate caspase-3. These results are supported by previous
observations where E2 was proven to protect rat NP cells against
apoptosis induced by IL-1b [8], or by levoﬂoxacin [9]. Interestingly,
the effects of E2 on IL-1b-induced NP cell apoptosis were only
partly blocked by GPR30 antagonist G36, but completely blocked
by the combination of classic ER antagonists ICI 182,780 and G36.
The data suggest that activation of GPR30 is necessary but not
sufﬁcient to mediate the full effect of E2 on IL-1b induced
apoptosis. Both GPR30 and classic ER are involved in E2 mediated
NP cell proliferation and survival. Caspases, belonging to a family of
cysteine proteases, are key mediators of the apoptosis pathway.
Caspase-3 is a downstream member of the caspase cascade and
acts as a central effector in the apoptotic pathway [38].
E2 signiﬁcantly inhibited caspase-3 activity triggered by IL-1b.
These results indicate that anti-apoptotic effect of E2 on NP cells is,
at least partly, mediated through a mechanism involving caspase-
3 activation.
Several studies have shown both in vitro [22,35,39] and in vivo
[40] that GPR30-speciﬁc agonists initiate multiple intracellular
signaling pathways through G-protein intermediates. Signals
include those mediated by changing levels of intracellular calcium
ions, lipid and protein kinase pathway activation and trans-
activation of membrane bound epidermal growth factor receptor
signaling [25]. Our study adds to this body of work, by being the
ﬁrst to show that GPR30 is expressed in the human disc NP, can
mediate E2 enhanced cell proliferation and inﬂuence cellular
survival in disc cells, thus providing a potential avenue for
promoting disc maintenance and repair. However, we realize a
methodological limitation in using pharmacological inhibitors ICI
182,780 and G36 for loss of function experiments. The ICI
182,780 is also an agonist and while this confounds deﬁning the
exact mechanisms underlying the results, a role for GPR30 is clear
[18]. Further studies are needed to identify the activation of
intracellular pathways in IVD cells through GPR30 mediated
estrogen signaling by gene silencing or knockout techniques.
Female menopause is associated with an increased risk of disc
degeneration [14,41], which may indicate the contribution of
estrogen withdrawal in the pathogenesis of disc degeneration
disease. Similarly, the incidence of L4–L5 spondylolisthesis is also
greater in women [42]. The effects of E2 mediated via GPR30 in disc
NP cells may stimulate the development of potential regenerative
strategies using speciﬁc GPR30 agonists or phytoestrogens that
could reduce the side effects of hormone replacement therapy for
women at risk of disc degenerative diseases.
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